Evidence map›Paper›PMID 27905063›Full record

ArticleTransgenic research2017

Efficient gene targeting in mouse zygotes mediated by CRISPR/Cas9-protein.

Chris J Jung, Junli Zhang, Elizabeth Trenchard, Kent C Lloyd, David B West, Barry Rosen, Pieter J de Jong

Abstract read
In one paragraph

Article in Transgenic research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Gene Therapy for Inherited Liver Disease: To Add or to Edit.International journal of molecular sciences · 2024
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Genetic cartography of longevity in humans and mice: Current landscape and horizons.Biochimica et biophysica acta. Molecular basis of disease · 2018
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chris J JungUniversity of California, San Francisco Benioff Children's Hospital Oakland Research Institute, Oakland, CA, 94609, USA.
Junli ZhangGladstone Institutes, San Francisco, CA, 94158, USA.
Elizabeth TrenchardWellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK.
Kent C LloydMouse Biology Program, University of California, Davis, CA, 95618, USA.
David B WestUniversity of California, San Francisco Benioff Children's Hospital Oakland Research Institute, Oakland, CA, 94609, USA.
Barry RosenWellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK.
Pieter J de JongUniversity of California, San Francisco Benioff Children's Hospital Oakland Research Institute, Oakland, CA, 94609, USA. pdejong@chori.org.ORCID 0000-0002-7972-5260

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium TCP Transfer to UC DavisUM1OD023221 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KC KENT LLOYD · 2016 to 2026
$45.7M
UCD Mutant Mouse Regional Resource CenterU42OD012210 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KC KENT LLOYD · 2012 to 2026
$29.2M
KOMP Phase II Mouse Production and CryopreservationU42OD011175 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2012 to 2015
$18.9M
KOMP Phase II Mouse PhenotypingU54HG006364 · NHGRI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2011 to 2015
$16.3M
Mouse Metabolic Phenotyping Center (MMPC) at UC DavisU24DK092993 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2011 to 2015
$4.1M
NCI NIH HHS P30 CA093373NHGRI NIH HHS U54 HG006364NIDDK NIH HHS U24 DK092993NIH HHS U42 OD011175NIH HHS U42 OD012210NIH HHS UM1 OD023221
6 · The paper itself

Abstract

The CRISPR/Cas9 system has rapidly advanced targeted genome editing technologies. However, its efficiency in targeting with constructs in mouse zygotes via homology directed repair (HDR) remains low. Here, we systematically explored optimal parameters for targeting constructs in mouse zygotes via HDR using mouse embryonic stem cells as a model system. We characterized several parameters, including single guide RNA cleavage activity and the length and symmetry of homology arms in the construct, and we compared the targeting efficiency between Cas9, Cas9nickase, and dCas9-FokI. We then applied the optimized conditions to zygotes, delivering Cas9 as either mRNA or protein. We found that Cas9 nucleo-protein complex promotes highly efficient, multiplexed targeting of circular constructs containing reporter genes and floxed exons. This approach allows for a one-step zygote injection procedure targeting multiple genes to generate conditional alleles via homologous recombination, and simultaneous knockout of corresponding genes in non-targeted alleles via non-homologous end joining.

Indexed as

AllelesAnimalsCRISPR-Cas SystemsDNA End-Joining RepairExonsGene TargetingHomologous RecombinationMiceRNA, Guide, CRISPR-Cas SystemsRNA, MessengerZygoteRNA, Guide, CRISPR-Cas SystemsRNA, MessengerCRISPRGene targetingTransgenic mouse model

Identifiers

PMID27905063
PMCPMC5350237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.